T1DM: Vitamin D Supplementation (2023)
Author and Year:
Treiber G, Prietl B, et al. 2015
PubMed ID:
Article Title:
Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.
Authors:
Treiber G, Prietl B, Fröhlich-Reiterer E, Lechner E, Ribitsch A, Fritsch M, Rami-Merhar B, Steigleder-Schweiger C, Graninger W, Borkenstein M, Pieber T
Journal:
Clinical Immunology (Orlando, Fla.)
Year of publication:
2015
Volume:
161
Issue:
2
Page numbers:
217-224
Study Design:
Randomized Controlled Trial
Risk of Bias Assessment Rating:
Low risk
Inclusion Criteria:
>6 years old; diabetes duration less than 3 months (diabetes onset was defined according to ADA criteria); plasma levels of calcium and creatinine in normal ranges.
Exclusion Criteria:
Preexisting hypercalcemia; any inflammatory systemic disease; disorders in calcium metabolism; kidney diseases; pregnancy
Research Purpose:
To evaluate the effects of a 12-month supplementation with cholecalciferol on the number and function of regulatory T cells (Tregs) on the frequencies of important immune cells in the peripheral blood and residual beta cell function in young patients with new-onset T1D.
Blinding efforts:
Double blind
Study Location:
Austria
Source(s) of Funding:
Government, Industry, Not-for-profit
Please specify names of funders:
EASD (European Association for the Study of Diabetes)
BioPersMed (which is funded by the Federal Ministry of Transport, Innovation and Technology (BMVIT) and the Federal Ministry of Economics and Labour/the Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ) and the Styrian Business Promotion Agency (SFG).
Fresenius Kabi, Graz, Austria (provided Oleovit D3)